Cytochrome P4502C9 (CYP2C9) allele frequencies in canadian native indian and inuit populations

被引:58
作者
Gaedigk, A
Casley, WL
Tyndale, RF
Sellers, EM
Jurima-Romet, M
Leeder, JS
机构
[1] Childrens Mercy Hosp & Clin, Div Pediat Clin Pharmacol, Kansas City, MO 64108 USA
[2] Hlth Canada, Biol & Genet Therapies Directorate, Ottawa, ON K1A 0L2, Canada
[3] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada
关键词
CYP2C9; polymorphism; genotyping; ethnic diversity;
D O I
10.1139/cjpp-79-10-841
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
CYP2C9 is the major P450 2C enzyme in human liver and contributes to the metabolism of a number of clinically important substrate drugs. This polymorphically expressed enzyme has been studied in Caucasian, Asian, and to some extent in African American populations, but little is known about the genetic variation in Native American populations. We therefore determined the 2C9*2 (Arg(144)Cys) and 2C9*3 (Ile(359)Leu) allele frequencies in 153 Native Canadian Indian (CNI) and 151 Inuit subjects by PCR-RFLP techniques. We also present genotyping data for two reference populations, 325 Caucasian (white North American) and 102 Chinese subjects. Genotyping analysis did not reveal any 2C9*4 alleles in the CNI, Inuit, Caucasian, or Chinese individuals. The 2C9*2 allele appears to be absent in Chinese and Inuit populations, but was present in CNI and Caucasian subjects at frequencies of 0.03 and 0.08-0.15, respectively. The 2C9*3 allele was not detected in the Inuit group, but occured in the CNI group (f = 0.06) at a frequency comparable to that of other ethnic groups. This group of Inuit individuals are the first population in which no 2C9*2 or *3 alleles have been detected so far. Therefore, these alleles may be extremely rare or absent, and unless other novel polymorphisms exist in this Inuit group one would not anticipate any CYP2C9 poor metabolizer subjects among this population.
引用
收藏
页码:841 / 847
页数:7
相关论文
共 33 条
[1]
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[3]
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population [J].
Aynacioglu, AS ;
Sachse, C ;
Bozkurt, A ;
Kortunay, S ;
Nacak, M ;
Schröder, T ;
Kayaalp, SO ;
Roots, I ;
Brockmöller, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :185-192
[4]
Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN
[5]
GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS [J].
DAHL, ML ;
YUE, QY ;
ROH, HK ;
JOHANSSON, I ;
SAWE, J ;
SJOQVIST, F ;
BERTILSSON, L .
PHARMACOGENETICS, 1995, 5 (03) :159-164
[6]
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].
Dickmann, LJ ;
Rettie, AE ;
Kneller, MB ;
Kim, RB ;
Wood, AJJ ;
Stein, CM ;
Wilkinson, GR ;
Schwarz, UI .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387
[7]
NAD(P)H:quinone oxidoreductase:: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations [J].
Gaedigk, A ;
Tyndale, RF ;
Jurima-Romet, M ;
Sellers, EM ;
Grant, DM ;
Leeder, JM .
PHARMACOGENETICS, 1998, 8 (04) :305-313
[8]
BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[9]
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].
Goldstein, JA ;
Ishizaki, T ;
Chiba, K ;
deMorais, SMF ;
Bell, D ;
Krahn, PM ;
Evans, DAP .
PHARMACOGENETICS, 1997, 7 (01) :59-64
[10]
Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients:: genetic analysis of the CYP2C9 locus [J].
Imai, J ;
Ieiri, I ;
Mamiya, K ;
Miyahara, S ;
Furuumi, H ;
Nanba, E ;
Yamane, M ;
Fukumaki, Y ;
Ninomiya, H ;
Tashiro, N ;
Otsubo, K ;
Higuchi, S .
PHARMACOGENETICS, 2000, 10 (01) :85-89